510 related articles for article (PubMed ID: 35782947)
1. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
Front Nutr; 2022; 9():906511. PubMed ID: 35782947
[TBL] [Abstract][Full Text] [Related]
2. The Gut Microbiome and Ferroptosis in MAFLD.
Ji J; Wu L; Wei J; Wu J; Guo C
J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
4. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study.
Tateda T; Iino C; Sasada T; Sato S; Igarashi G; Kawaguchi S; Mikami K; Endo T; Sawada K; Mikami T; Fukuda S; Nakaji S; Sakuraba H
PLoS One; 2022; 17(11):e0277930. PubMed ID: 36417462
[TBL] [Abstract][Full Text] [Related]
6. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
[TBL] [Abstract][Full Text] [Related]
7. Vitamin C and vitamin D
Chen Q; Zhao L; Mei L; Zhao X; Han P; Liu J; Meng C; Li R; Zhong R; Wang K; Li J
Front Pharmacol; 2023; 14():1163694. PubMed ID: 37089915
[No Abstract] [Full Text] [Related]
8. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
9. Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:
Yuan H; Wu X; Wang X; Zhou JY; Park S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396863
[TBL] [Abstract][Full Text] [Related]
10. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
Dongoran RA; Tu FC; Liu CH
Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
[TBL] [Abstract][Full Text] [Related]
11. Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD).
Guo Q; Li Y; Dai X; Wang B; Zhang J; Cao H
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686754
[TBL] [Abstract][Full Text] [Related]
12. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
[TBL] [Abstract][Full Text] [Related]
14. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
19. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.
Yang K; Song M
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764755
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.
Nováková B
Cas Lek Cesk; 2022; 161(2):65-71. PubMed ID: 35728960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
